对比疗效研究的方法标准:医疗保险药品价格谈判证据审查的考虑
Riddhi Doshi1, Victoria Divino1, Luke Greenwalt2
1Real World Solutions, IQVIA, Durham, NC, USA.
Expert review of pharmacoeconomics & outcomes research
|January 12, 2025
概括
"通货膨胀减缓法案"旨在降低美国医疗保险药品价格. 关于药物价格谈判 (DPN) 的新指南需要更清晰的方法来进行比较有效性研究,考虑数据质量和健康公平.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 基于证据的医学是基于证据的医学.
背景情况:
- 2022年通货膨胀减缓法案 (IRA) 要求美国医疗保险受益人降低处方药价格.
- 医疗保险和医疗补助服务中心 (CMS) 在2024年5月发布了医疗保险药品价格谈判 (DPN) 计划的指导草案.
- 对于10种被选中的药物,DPN谈判的第一轮谈判已经完成,在2023年8月确定药物后.
研究的目的:
- 评估为DPN计划提交的比较有效性研究 (CER) 研究的方法指南.
- 识别CMS当前指导中关于DPN的CER方法的缺口.
- 提出建议,为DPN证据制定强有力的方法指南.
主要方法:
- 在PubMed上进行了搜索,以确定相关的CER研究和方法.
- 审查了来自美国和国际监管机构网站的资源.
- 分析重点是确定DPN的方法指南中的最佳实践和差距.
主要成果:
- 最新的CMS指南承认研究限制,偏见,不确定性和可概括性的重要性.
- 然而,针对DPN提交的CER研究的具体方法指南被发现很少.
- 联邦和非联邦组织的现有指导方针为制定DPN特定指导提供了基础.
结论:
- 为DPN证据制定全面的方法指南至关重要.
- 这些准则应涵盖数据质量,透明度,研究设计,结果评估,偏见,混和不确定性.
- 建议在为DPN定制时与现有框架保持一致,包括对特定人群和健康公平的考虑.
相关概念视频
01:16Bioequivalence: Overview
944
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
944
01:22Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:12Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96
01:03Drug Control Governance: Regulatory Bodies and Their Impact
146
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
146